OTCMKTS:SEOVF Sernova (SEOVF) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free SEOVF Stock Alerts $0.33 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.33▼$0.3350-Day Range$0.29▼$0.5152-Week Range$0.29▼$0.83Volume11,100 shsAverage Volume16,040 shsMarket Capitalization$100.22 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Sernova alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Sernova Stock (OTCMKTS:SEOVF)Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.Read More SEOVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SEOVF Stock News HeadlinesMarch 11, 2024 | marketwatch.comSernova Names Nicholas Rossettos Interim CFOJanuary 29, 2024 | msn.comSernova reports anticipated 2024 milestonesApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… November 27, 2023 | msn.comSernova gets FDA orphan drug, rare pediatric designations for hemophilia ANovember 14, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Tuesday (SVA)October 30, 2023 | finance.yahoo.comSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint CongressSeptember 29, 2023 | finance.yahoo.comSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual MeetingSeptember 7, 2023 | finance.yahoo.comSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch DeviceApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… September 5, 2023 | marketwatch.comSernova Appoints Cynthia Pussinen as Chief ExecutiveSeptember 5, 2023 | seekingalpha.comSernova appoints CEOJune 26, 2023 | markets.businessinsider.comSernova (SVA) Receives a Buy from H.C. WainwrightJune 22, 2023 | finance.yahoo.comSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific SessionsJune 16, 2023 | finance.yahoo.comSernova to Participate in Upcoming Truist Securities Cell Therapy SymposiumJune 15, 2023 | markets.businessinsider.comEchelon Wealth Partners Remains a Buy on Sernova (SVA)May 31, 2023 | finance.yahoo.comSernova Announces Executive Alignment and Appoints New Board ChairMay 8, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Monday (SVA)April 28, 2023 | theglobeandmail.comClosing Bell: Sernova Corp flat on Thursday (SVA)April 25, 2023 | finance.yahoo.comConcerned Shareholders of Sernova Corp. Wish to Thank All ShareholdersApril 10, 2023 | finance.yahoo.comSernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the MedApril 6, 2023 | finanznachrichten.deSernova Corp.: Sernova Responds to Dissident Shareholders' Misleading Statements and Provides Corporate UpdatesMarch 23, 2023 | finance.yahoo.comAdvance Notice Filed with Sernova Corp. for the Nomination of Two Director NomineesMarch 22, 2023 | finance.yahoo.comSernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023March 2, 2023 | finance.yahoo.comSernova to Participate in Upcoming Roth and Oppenheimer Investor ConferencesJanuary 30, 2023 | marketwatch.comSernova Shares Climb After Study Update on System to Preserve Thyroid FunctionJanuary 30, 2023 | uk.news.yahoo.comSernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total ThyroidectomyJanuary 30, 2023 | finance.yahoo.comSernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total ThyroidectomySee More Headlines Receive SEOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/23/2024Next Earnings (Estimated)6/12/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:SEOVF CUSIPN/A CIK1491434 Webwww.sernova.com Phone(519) 858-5184Fax519-858-5184EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+354.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-226.64% Return on Assets-145.26% Debt Debt-to-Equity Ratio0.14 Current Ratio1.20 Quick Ratio1.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book11.01Miscellaneous Outstanding Shares303,410,000Free FloatN/AMarket Cap$100.22 million OptionableNot Optionable Beta1.16 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMs. Cynthia PussinenCEO & DirectorDr. Philip M. Toleikis B.A.M.Sc., Ph.D., President, CTO, Director of Technology & DirectorDr. Modestus Obochi M.B.A.Ph.D., Chief Business OfficerDr. Frank Shannon M.D.Vice President of Clinical Development & Regulatory AffairsMr. Nicholas J. Rossettos CPA (Age 58)M.B.A., Interim Chief Financial Officer Mr. Douglas MaretChief Science OfficerMr. Christopher BarnesVice President of Investor RelationsMore ExecutivesKey CompetitorsPDS BiotechnologyNASDAQ:PDSBEmergent BioSolutionsNYSE:EBSIO BiotechNASDAQ:IOBTCartesian TherapeuticsNASDAQ:RNACAnixa BiosciencesNASDAQ:ANIXView All Competitors SEOVF Stock Analysis - Frequently Asked Questions Should I buy or sell Sernova stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sernova in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SEOVF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEOVF, but not buy additional shares or sell existing shares. View SEOVF analyst ratings or view top-rated stocks. What is Sernova's stock price target for 2024? 1 Wall Street analysts have issued 12 month price targets for Sernova's shares. Their SEOVF share price targets range from $1.50 to $1.50. On average, they expect the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 354.1% from the stock's current price. View analysts price targets for SEOVF or view top-rated stocks among Wall Street analysts. How have SEOVF shares performed in 2024? Sernova's stock was trading at $0.5328 at the beginning of 2024. Since then, SEOVF stock has decreased by 38.0% and is now trading at $0.3303. View the best growth stocks for 2024 here. Are investors shorting Sernova? Sernova saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 110,400 shares, a decrease of 19.9% from the February 29th total of 137,900 shares. Based on an average trading volume of 47,100 shares, the days-to-cover ratio is presently 2.3 days. View Sernova's Short Interest. When is Sernova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our SEOVF earnings forecast. How were Sernova's earnings last quarter? Sernova Corp. (OTCMKTS:SEOVF) released its quarterly earnings results on Monday, March, 18th. The company reported ($0.02) earnings per share for the quarter. How do I buy shares of Sernova? Shares of SEOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SEOVF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIncredible Opportunity to Retire FAST!Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sernova Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
